On the 29th, the Beijing Pharmaceutical and Medical Device Innovation Service Station (Yizhuang Station) was inaugurated in the Beijing Economic and Technological Development Zone. The biotechnology and big health industry is one of the four leading industries in the Beijing Economic Development Zone. There are more than 3,500 enterprises in various subdivisions such as medicine, equipment, health care, and services. Last year, the industrial output value of Yizhuang's medical and health industry exceeded 90 billion yuan , accounting for 47.9% of the total in Beijing.
The relevant person in charge of the Beijing Municipal Food and Drug Administration stated that the innovative service station (Yizhuang Station) will be established in the Beijing Economic Development Zone, and will further integrate various resources, improve the working mechanism, and increase service guidance for the registration and marketing of innovative drugs and devices , and become a "fertile soil" for "nourishing" the review and approval of medical devices in the southern area of Beijing, which will surely drive the continuous improvement of the vitality of the regional industry. The Municipal Food and Drug Administration will work with the Beijing Economic Development Zone to actively build multi-channel and multi-level enterprise service channels, further optimize the business environment, and continue to promote the innovation of the biomedical industry system and the opening of the industrial chain.
Beijing Drug and Medical Device Innovation Service Station (Yizhuang Station) will provide biopharmaceutical companies with six major aspects including personnel training, customized consulting, pre-evaluation services, subject research, platform construction and brand building, and 12 work contents in One-stop service within.
As the landing area of the Innovation Service Station (Yizhuang Station), Beijing Economic Development Zone is speeding up the construction of a global industrial highland of "intelligent manufacturing of new drugs". According to the relevant person in charge of the Beijing Economic Development Zone, the biotechnology and big health industry is one of the four leading industries in the Economic Development Zone, covering more than 3,500 enterprises in various sub-sectors such as pharmaceuticals, equipment, health care, and services, running through innovative research and development, clinical services , Large-scale production, commercial circulation, and terminal application of the whole industry chain. In 2022, the industrial output value of the medical and health industry in the Beijing Economic Development Zone will exceed 90 billion yuan, accounting for 47.9% of the city's total.
In February of this year, the Beijing Economic and Technological Development Zone issued the "Three-Year Action Plan for Accelerating the Construction of a Global "Intelligent Manufacturing of New Drugs" Industry Highland (2023-2025)", which established a 1+N policy system ("1" means biomedicine Universal policies for the health industry, "N" is a special policy for subdividing the track), providing a full life cycle service guarantee for the pharmaceutical industry from the aspects of focusing on innovation, attracting talents and cultivating talents, spatial aggregation, and optimizing ecology.
In recent years, Beijing Economic and Technological Development Zone has continued to support the transformation of innovative achievements while exerting the effect of attracting leading enterprises. Since 2021, 4 Class I innovative drugs and 9 innovative medical devices independently developed by 11 companies in the region, including China Cell, Yiyi Bio, Qianglian Zhichuang, and Huaruibo, have been approved for marketing. According to incomplete statistics, in 2023, there will be nearly 100 innovative drugs and medical devices in the clinical trials and approval stages.
In the next step, the Beijing Economic and Technological Development Zone will give full play to the role of the innovation service station as a platform to provide strong support for the accelerated emergence of innovative products, and help more innovative drugs and medical devices to enter the market and serve the people.
Zhang Liming, the second-level inspector of the Comprehensive Department of the State Food and Drug Administration, Yu Haibo, Party Secretary of the Beijing Municipal Food and Drug Administration, Qu Haopeng, Deputy Director of the Municipal Food and Drug Administration, Zhang Qiang, Secretary of the Beijing Economic Development Zone Working Committee, and Shen Yonggang, Deputy Director of the Economic Development Zone Management Committee , Liu Li and more than 50 business representatives attended the unveiling ceremony.
微信扫一扫打赏
